First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report
POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M–protein, skin changes syndrome) is a rare condition due to an underlying plasma cell neoplasm whose clinical presentation can be various so it could lead to delayed diagnosis and treatment. The pathogenesis of the syndrome is not well u...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Leukemia Research Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213048924000815 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850117660182839296 |
|---|---|
| author | E. Amabile F. Fazio M. Martelli MT. Petrucci |
| author_facet | E. Amabile F. Fazio M. Martelli MT. Petrucci |
| author_sort | E. Amabile |
| collection | DOAJ |
| description | POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M–protein, skin changes syndrome) is a rare condition due to an underlying plasma cell neoplasm whose clinical presentation can be various so it could lead to delayed diagnosis and treatment. The pathogenesis of the syndrome is not well understood, and its therapy is adapted from other plasma cell disorders with the aim of alleviating symptoms, decreasing end-organ damage, improving quality of life and prolonging overall survival. We report a case of a 71 years-old woman who has been treated with continuous DRd (daratumumab, lenalidomide and dexamethasone) scheme. |
| format | Article |
| id | doaj-art-42deabaece1d482a9d30c5112dfa0be5 |
| institution | OA Journals |
| issn | 2213-0489 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Leukemia Research Reports |
| spelling | doaj-art-42deabaece1d482a9d30c5112dfa0be52025-08-20T02:36:03ZengElsevierLeukemia Research Reports2213-04892024-01-012210049110.1016/j.lrr.2024.100491First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case reportE. Amabile0F. Fazio1M. Martelli2MT. Petrucci3Corresponding author.; Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Azienda Policlinico Umberto I, Rome, ItalyHematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Azienda Policlinico Umberto I, Rome, ItalyHematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Azienda Policlinico Umberto I, Rome, ItalyHematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Azienda Policlinico Umberto I, Rome, ItalyPOEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M–protein, skin changes syndrome) is a rare condition due to an underlying plasma cell neoplasm whose clinical presentation can be various so it could lead to delayed diagnosis and treatment. The pathogenesis of the syndrome is not well understood, and its therapy is adapted from other plasma cell disorders with the aim of alleviating symptoms, decreasing end-organ damage, improving quality of life and prolonging overall survival. We report a case of a 71 years-old woman who has been treated with continuous DRd (daratumumab, lenalidomide and dexamethasone) scheme.http://www.sciencedirect.com/science/article/pii/S2213048924000815POEMSPlasma cell disorderVEGF |
| spellingShingle | E. Amabile F. Fazio M. Martelli MT. Petrucci First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report Leukemia Research Reports POEMS Plasma cell disorder VEGF |
| title | First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report |
| title_full | First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report |
| title_fullStr | First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report |
| title_full_unstemmed | First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report |
| title_short | First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report |
| title_sort | first line therapy with daratumumab lenalidomide and dexamethasone for patient with poems syndrome a case report |
| topic | POEMS Plasma cell disorder VEGF |
| url | http://www.sciencedirect.com/science/article/pii/S2213048924000815 |
| work_keys_str_mv | AT eamabile firstlinetherapywithdaratumumablenalidomideanddexamethasoneforpatientwithpoemssyndromeacasereport AT ffazio firstlinetherapywithdaratumumablenalidomideanddexamethasoneforpatientwithpoemssyndromeacasereport AT mmartelli firstlinetherapywithdaratumumablenalidomideanddexamethasoneforpatientwithpoemssyndromeacasereport AT mtpetrucci firstlinetherapywithdaratumumablenalidomideanddexamethasoneforpatientwithpoemssyndromeacasereport |